3D0E

Crystal structure of human Akt2 in complex with GSK690693


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2 Å
  • R-Value Free: 0.246 
  • R-Value Work: 0.206 

wwPDB Validation 3D Report Full Report


This is version 1.3 of the entry. See complete history

Literature

Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase.

Heerding, D.A.Rhodes, N.Leber, J.D.Clark, T.J.Keenan, R.M.Lafrance, L.V.Li, M.Safonov, I.G.Takata, D.T.Venslavsky, J.W.Yamashita, D.S.Choudhry, A.E.Copeland, R.A.Lai, Z.Schaber, M.D.Tummino, P.J.Strum, S.L.Wood, E.R.Duckett, D.R.Eberwein, D.Knick, V.B.Lansing, T.J.McConnell, R.T.Zhang, S.Minthorn, E.A.Concha, N.O.Warren, G.L.Kumar, R.

(2008) J.Med.Chem. 51: 5663-5679

  • DOI: 10.1021/jm8004527

  • PubMed Abstract: 
  • Overexpression of AKT has an antiapoptotic effect in many cell types, and expression of dominant negative AKT blocks the ability of a variety of growth factors to promote survival. Therefore, inhibitors of AKT kinase activity might be useful as monot ...

    Overexpression of AKT has an antiapoptotic effect in many cell types, and expression of dominant negative AKT blocks the ability of a variety of growth factors to promote survival. Therefore, inhibitors of AKT kinase activity might be useful as monotherapy for the treatment of tumors with activated AKT. Herein, we describe our lead optimization studies culminating in the discovery of compound 3g (GSK690693). Compound 3g is a novel ATP competitive, pan-AKT kinase inhibitor with IC 50 values of 2, 13, and 9 nM against AKT1, 2, and 3, respectively. An X-ray cocrystal structure was solved with 3g and the kinase domain of AKT2, confirming that 3g bound in the ATP binding pocket. Compound 3g potently inhibits intracellular AKT activity as measured by the inhibition of the phosphorylation levels of GSK3beta. Intraperitoneal administration of 3g in immunocompromised mice results in the inhibition of GSK3beta phosphorylation and tumor growth in human breast carcinoma (BT474) xenografts.


    Organizational Affiliation

    Oncology Center of Excellence for Drug Discovery, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, USA. dirk.a.heerding@gsk.com




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
RAC-beta serine/threonine-protein kinase
A, B
335Homo sapiensGene Names: AKT2
EC: 2.7.11.1
Find proteins for P31751 (Homo sapiens)
Go to Gene View: AKT2
Go to UniProtKB:  P31751
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
G93
Query on G93

Download SDF File 
Download CCD File 
A, B
4-{2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[(3S)-piperidin-3-ylmethoxy]-1H-imidazo[4,5-c]pyridin-4-yl}-2-methylbut-3-yn-2-ol
GSK690693
C21 H27 N7 O3
KGPGFQWBCSZGEL-ZDUSSCGKSA-N
 Ligand Interaction
Modified Residues  1 Unique
IDChainsTypeFormula2D DiagramParent
TPO
Query on TPO
A, B
L-PEPTIDE LINKINGC4 H10 N O6 PTHR
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2 Å
  • R-Value Free: 0.246 
  • R-Value Work: 0.206 
  • Space Group: P 32
Unit Cell:
Length (Å)Angle (°)
a = 116.489α = 90.00
b = 116.489β = 90.00
c = 45.119γ = 120.00
Software Package:
Software NamePurpose
PDB_EXTRACTdata extraction
DENZOdata reduction
SCALEPACKdata scaling
REFMACrefinement

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

Revision History 

  • Version 1.0: 2008-10-21
    Type: Initial release
  • Version 1.1: 2011-07-13
    Type: Advisory, Version format compliance
  • Version 1.2: 2016-12-28
    Type: Non-polymer description
  • Version 1.3: 2017-10-25
    Type: Refinement description